Skip to content

Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder.

M J Spriggs, Hannes Kettner, R L Carhart-Harris

Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity May 1, 2021 DOI: 10.1007/s40519-020-01000-8 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Prospective cohort study Peer reviewed
Sample size 28
Population Individuals reporting a lifetime eating disorder diagnosis planning to take a psychedelic drug
Duration 1-2 weeks before and 2 weeks after a psychedelic experience
Topics Depression
Keywords Anorexia Binge eating disorder Bulimia Longitudinal Prospective online survey Psychedelics
Key findings Depression and wellbeing scores improved after a psychedelic experience in people with a lifetime eating disorder diagnosis.

Abstract

Psychedelic therapy is showing promise for a broad range of mental health conditions, indicative of a transdiagnostic action. While the efficacy of symptom-focused treatments for eating disorders (EDs) is limited, improved mental health and psychological wellbeing are thought to contribute to greater treatment outcomes. This study provides the first quantitative exploration of the psychological effects of psychedelics in those reporting an ED diagnosis. Prospective, online data were collected from individuals planning to take a psychedelic drug. Twenty-eight participants reporting a lifetime ED diagnosis completed measures of depressive symptomology (Quick Inventory of Depressive Symptomology; QIDS-SR16) and psychological wellbeing (Warwick-Edinburgh Mental Wellbeing Scale; WEMWBS) 1-2 weeks before, and 2 weeks after a psychedelic experience. Twenty-seven of these participants also completed a measure of emotional breakthrough [Emotional Breakthrough Inventory (EBI)] in relation to the acute psychedelic experience. Bayesian t tests demonstrated overwhelming evidence for improvements in depression and wellbeing scores following the psychedelic experience. Marginal evidence was also found for a correlation between emotional breakthrough and the relevant mental health improvements. These findings provide supportive evidence for positive psychological aftereffects of a psychedelic experience that are relevant to the treatment of EDs. It is hoped that this will encourage further research and will bolster initiatives to directly examine the safety and efficacy of psychedelic assisted therapy as a treatment of EDs in future clinical trials. Level III, cohort study.

Comparable studies

Other observational and cohort studies on depression, most cited first.

Study Year Design Participants
Metacognitive awareness and prevention of relapse in depression: Empirical evidence. Residually depressed patients and nondepressed controls; recovered depressed patients 2002 Observational cohort with intervention components
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression 2017 Observational cohort n = 19
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report Patients with a depressive disorder 2015 Observational study
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Patients with treatment-resistant major depressive disorder 2012 Observational cohort n = 30
Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome Healthy controls and actively depressed patients with treatment-resistant depression... 2017 Observational cohort n = 59

Citations in the library

Cited by 78

and 73 more in the library

Cites 5

Related reading

Explore topics

Depression Psychedelic-assisted therapy